Design Therapeutics (DSGN) Total Liabilities (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Total Liabilities data on file, last reported at $12.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 29.64% year-over-year to $12.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.4 million (up 29.64% YoY), and the FY2025 full-year result was $13.7 million, up 37.05% from the prior year.
• Total Liabilities slipped to $12.4 million in Q1 2026, from $13.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $14.9 million in Q3 2023 to a low of $8.3 million in Q2 2024.
• A 5-year average of $11.4 million and a median of $11.9 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 203.78% in 2022 and tumbled 43.78% in 2024, its largest moves.
• Tracing DSGN's Total Liabilities over 5 years: stood at $13.8 million in 2022, then dropped by 13.53% to $12.0 million in 2023, then decreased by 16.39% to $10.0 million in 2024, then surged by 37.05% to $13.7 million in 2025, then fell by 9.58% to $12.4 million in 2026.
• Business Quant data shows DSGN's Total Liabilities at $12.4 million in Q1 2026, $13.7 million in Q4 2025, and $12.0 million in Q3 2025.